Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells.
Nguyen THO, Rowntree LC, Allen LF, Chua BY, Kedzierski L, Lim C, Lasica M, Tennakoon GS, Saunders NR, Crane M, Chee L, Seymour JF, Anderson MA, Whitechurch A, Clemens EB, Zhang W, Chang SY, Habel JR, Jia X, McQuilten HA, Minervina AA, Pogorelyy MV, Chaurasia P, Petersen J, Menon T, Hensen L, Neil JA, Mordant FL, Tan HX, Cabug AF, Wheatley AK, Kent SJ, Subbarao K, Karapanagiotidis T, Huang H, Vo LK, Cain NL, Nicholson S, Krammer F, Gibney G, James F, Trevillyan JM, Trubiano JA, Mitchell J, Christensen B, Bond KA, Williamson DA, Rossjohn J, Crawford JC, Thomas PG, Thursky KA, Slavin MA, Tam CS, Teh BW, Kedzierska K. Nguyen THO, et al. Among authors: gibney g. Cell Rep Med. 2023 Apr 18;4(4):101017. doi: 10.1016/j.xcrm.2023.101017. Epub 2023 Mar 27. Cell Rep Med. 2023. PMID: 37030296 Free PMC article.
Delayed cutaneous hypersensitivities to COVID-19 vaccination: Phenotypic distribution and tolerability of vaccine rechallenge.
De Luca JF, Awad A, Vogrin S, Waldron JL, McInnes K, Gibney G, Hall R, Douglas AP, Chua KYL, Holmes NE, Trubiano JA. De Luca JF, et al. Among authors: gibney g. J Allergy Clin Immunol Pract. 2023 Aug;11(8):2605-2607.e2. doi: 10.1016/j.jaip.2023.04.045. Epub 2023 May 11. J Allergy Clin Immunol Pract. 2023. PMID: 37178767 Free PMC article. No abstract available.
Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot randomised controlled trial.
Rose M, Holmes N, Eastwood G, Vogrin S, James F, Phung M, Barnes S, Murfin B, Rogers B, Lambros B, Peel T, Gibney G, Slavin M, Trubiano J. Rose M, et al. Among authors: gibney g. Pilot Feasibility Stud. 2023 Jul 20;9(1):126. doi: 10.1186/s40814-023-01337-8. Pilot Feasibility Stud. 2023. PMID: 37475038 Free PMC article.
Durability of immune responses after drug reaction with eosinophilia and systemic symptoms.
Awad A, Mouhtouris E, Clatch A, James F, Chua KYL, Holmes NE, Gibney G, Rose M, Copaescu A, Goh MS, Mackay LK, Christo SN, Gordon C, Philips EJ, Trubiano JA. Awad A, et al. Among authors: gibney g. J Allergy Clin Immunol Pract. 2024 Jan;12(1):232-235.e2. doi: 10.1016/j.jaip.2023.09.020. Epub 2023 Sep 29. J Allergy Clin Immunol Pract. 2024. PMID: 37778629 No abstract available.
Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S. Munster P, et al. Among authors: gibney gt. Cancer Res Commun. 2024 Mar 13;4(3):785. doi: 10.1158/2767-9764.CRC-24-0133. Cancer Res Commun. 2024. PMID: 38477691 Free PMC article. No abstract available.
Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation.
Rogava M, Aprati TJ, Chi WY, Melms JC, Hug C, Davis SH, Earlie EM, Chung C, Deshmukh SK, Wu S, Sledge G, Tang S, Ho P, Amin AD, Caprio L, Gurjao C, Tagore S, Ngo B, Lee MJ, Zanetti G, Wang Y, Chen S, Ge W, Melo LMN, Allies G, Rösler J, Gibney GT, Schmitz OJ, Sykes M, Creusot RJ, Tüting T, Schadendorf D, Röcken M, Eigentler TK, Molotkov A, Mintz A, Bakhoum SF, Beyaz S, Cantley LC, Sorger PK, Meckelmann SW, Tasdogan A, Liu D, Laughney AM, Izar B. Rogava M, et al. Among authors: gibney gt. Nat Cancer. 2024 Mar;5(3):433-447. doi: 10.1038/s43018-023-00704-x. Epub 2024 Jan 29. Nat Cancer. 2024. PMID: 38286827
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Weber JS, et al. Among authors: gibney gt. Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. Lancet. 2024. PMID: 38246194 Clinical Trial.
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S. Munster P, et al. Among authors: gibney gt. Cancer Res Commun. 2023 Dec 19;3(12):2572-2584. doi: 10.1158/2767-9764.CRC-22-0461. Cancer Res Commun. 2023. PMID: 38115208 Free PMC article. Clinical Trial.
117 results